SCHEMBL2943855

SCHEMBL2943855

FC(F)(F)Oc1cccc(-c2cnc3ccc(NCc4ccncc4)nn23)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 17/20 0.82
FYN P06241 1/20 0.67
DYRK1A Q13627 1/20 0.67
KCNH2 Q12809 2/20 0.63
GAK O14976 1/20 0.63
STK10 O94804 1/20 0.63
YES1 P07947 1/20 0.63
RET P07949 1/20 0.63
PDGFRB P09619 1/20 0.63
CSNK2A2 P19784 1/20 0.63
FLT3 P36888 1/20 0.63
ACVR1 Q04771 1/20 0.63
PKN1 Q16512 1/20 0.63
PIM3 Q86V86 1/20 0.63
HASPIN Q8TF76 1/20 0.63
SIK2 Q9H0K1 1/20 0.63
SLK Q9H2G2 1/20 0.63
BMP2K Q9NSY1 1/20 0.63
PIM2 Q9P1W9 1/20 0.63
PRKAG2 Q9UGJ0 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13223358 0.90 PIM1 (0.70) PIM1FYNDYRK1AMKNK1
SCHEMBL103188 0.90 PIM1 (1.00) PIM1FYNKCNH2GAKSTK10
SCHEMBL136986 0.89 PIM1 (1.00) PIM1FYNDYRK1AKCNH2GAK
SCHEMBL2945398 0.87 FYN (0.74) PIM1FYNMKNK1
SCHEMBL2948030 0.86 PIM1 (0.72) PIM1FYNDYRK1AKCNH2GAK
SCHEMBL2947680 0.86 PIM1 (0.77) PIM1KCNH2GAKSTK10YES1
SCHEMBL2943833 0.85 FYN (0.71) PIM1FYNDYRK1AKCNH2MKNK1
SCHEMBL12761389 0.83 PIM1 (0.74) PIM1KCNH2GAKSTK10YES1
SCHEMBL2948807 0.83 PIM1 (1.00) PIM1FYNKCNH2GAKSTK10
SCHEMBL102542 0.82 PIM1 (1.00) PIM1KCNH2GAKSTK10YES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 PIM1 365/4885FYN 421/4885DYRK1A 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.